Concepedia

G. S. Falchook

GS

16

Publications

928

Citations

13

H-Index

2009

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

G. S. Falchook is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, cancer research, and medicine.

Top concepts

Publications per year

2009–2014

16

Publications

16

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

, , +20

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

G. S. Falchook, Francisco Vega, Nam H. Dang et al. · Annals of Oncology · 2009 · 152 citations · Full text

, , +7

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence et al. · Journal of Clinical Oncology · 2011 · 122 citations

, , +19

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors

David S. Hong, Haby Henary, G. S. Falchook et al. · Investigational New Drugs · 2014 · 90 citations

, , +9

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

Raoul Tibes, G. S. Falchook, Daniel D. Von Hoff et al. · Journal of Clinical Oncology · 2010 · 42 citations

, , +22

Rows per page

1–5 of 16